January 20, 2020   Brolucizumab in the real world: What it means for physicians, patients Retinal specialists are ushering in a new year with the availability of a new anti–vascular endothelial growth factor (VEGF) therapy since the recent FDA approval of brolucizumab for the treatment of patients with wet age-related macular degeneration (AMD). Learn more ADVERTISEMENT   Coming to terms with ‘ultra-widefield’ and ‘widefield’ imaging The International Widefield Imaging Study Group (IWISG)—a physician panel with expertise in retinal imaging—has released recommendations for classifications and guidelines for defining “widefield” and “ultra-widefield” imaging. Learn more What deep learning means for future of diabetic retinopathy screening The Deep learning could have an application in the diagnosis and management of retinal diseases. Here’s what clinicians need to know. Learn more